We recently collaborated with Lent Innovations to explore critical issues in pediatric epinephrine injectors. Our latest article features insights from Dr. Annie Lent and our Deputy Head of Drug Delivery, Steve Augustyn.
Sergio explores single-use endoscopes and our framework for designing a greener solution. Focusing on sustainability, balancing environmental benefits with clinical outcomes and commercial opportunities through creative, data-driven strategies.
Insights from Industry Experts on Training for Patient Technique, the Value of Connected Devices, and the Shift to Low GWP pMDIs.
We are honored to announce our involvement in a remarkable awareness campaign with Cure Usher, Havas Lynx, and Push Films: the world's first 'touchable memory' device.
Multidisciplinary teams with diverse industry experience can dramatically speed up your new product development, securing you first-mover advantage.
In a recent Q&A with Healthcare Packaging, CDP’s Clare Beddoes and Stephen Augustyn discuss the latest trends in on-body large volume injectors (LVIs) and what they expect to see in 2024.
Explore five exciting developments in the field of oncology and how advances in diagnostics, data analytics, cell biology and delivery devices are enabling oncology companies to bring the hope of longer, healthier lives.
Mark Allen, Andrew Fiorini, and Shai Assia discuss the need to develop delivery devices early when formulating nasally delivered drugs for systemic and local action, and a method by which the route to clinic can be made easier, faster and cheaper.
In a recent investigation on digital health innovation in the UK, we uncovered several hurdles that hinder progress. Here, we outline five and signpost resources to help innovators overcome them.
Sergio and Alejandra explore emerging implantable neuromodulation therapies that are opening new possibilities in the rapidly evolving field.
Bioprocessing technology is developing rapidly due to the automation of data collection and processing. But as Richard Owen (Head of Biology) and Arianna Rech (Bioprocessing Lead) explain, there is more that needs to be done to keep up with industry demand.
In the fourth of our GenAI series, we’ve prompted the LLM to give us insights. So for the Chatbot’s perspective, here is the response from GPT-4 - verbatim.